Previous studies have consistently reported a worse prognosis for CHEK2 c.1100delC breast cancer patients [3,5,6,11] and a higher incidence of recurrent disease and distant metastatic disease than non-carriers [7,8,12]. Here, CHEK2 is linked to breast cancer.